The complex physiological process of bone formation and continuous remodelling of bone during fracture healing is known as bone regeneration. Bone regeneration is important in clinical conditions such as trauma caused skeletal reconstruction, bone infection, tumour resection and skeletal abnormalities. Currently, bone graft, free fibula vascularised graft and allograft implantation are considered as gold standard therapy. In autologous bone graft regeneration, the donor’s contribution is limited and involves several complications.
Furthermore, in oral health or periodontal disease treatment, bone regeneration leads to damaging of periodontal ligament and alveolar bone. The aim of treating periodontal disease is to prevent further disease progression. Hence, considering this treatment concern, bone regeneration is an excellent treatment for periodontal diseases. Bone regeneration involves histological and biological changes associated with inflammation, blood supply, formation of fibrous tissue and bony callus.
The ongoing research and development of biomaterials for bone and cartilage regeneration is driving the growth of the global bone regeneration materials market. The biomaterials used for regeneration should be favourable to proliferation, cell adhesion, and differentiation to confirm rapid regeneration process at the site of injury.
Market Dynamics
Launch of bone regeneration products by key players is expected to drive growth of global bone regeneration materials market. For instance, in May 2020, Orthocell Ltd Company completed the submission 510(k) clearance to the U.S FDA to receive approval for marketing its CelGro product used in dental guided bone and soft tissue regeneration applications. The company will launch this product in the U.S market after receiving approval from the U.S FDA. The company is focused on marketing and building its network of key opinion leaders across the U.S. This will help company to promote and position its product in the U.S market.
Similarly, in 2019, Biogennix LLC, an osteobiologics company that manufactures bone graft products used for bone fusion procedures, received the U.S FDA 510(k) clearance for Agilon, a new collagen-enhanced bone graft material. The company has made this product commercially available in the U.S market. With the launch, the company is expanding its product portfolio and address the increasing demand from the U.S market.
Key features of the study:
Detailed Segmentation:
Global bone regeneration materials market, By Product Type:
Global bone regeneration materials market, By Application:
Global bone regeneration materials market, By Region:
By Country:
By Country:
By Country:
By Country:
By Country:
By Country/Region:
“*” marked represents similar segmentation in other categories in the respective section.
Furthermore, in oral health or periodontal disease treatment, bone regeneration leads to damaging of periodontal ligament and alveolar bone. The aim of treating periodontal disease is to prevent further disease progression. Hence, considering this treatment concern, bone regeneration is an excellent treatment for periodontal diseases. Bone regeneration involves histological and biological changes associated with inflammation, blood supply, formation of fibrous tissue and bony callus.
The ongoing research and development of biomaterials for bone and cartilage regeneration is driving the growth of the global bone regeneration materials market. The biomaterials used for regeneration should be favourable to proliferation, cell adhesion, and differentiation to confirm rapid regeneration process at the site of injury.
Market Dynamics
Launch of bone regeneration products by key players is expected to drive growth of global bone regeneration materials market. For instance, in May 2020, Orthocell Ltd Company completed the submission 510(k) clearance to the U.S FDA to receive approval for marketing its CelGro product used in dental guided bone and soft tissue regeneration applications. The company will launch this product in the U.S market after receiving approval from the U.S FDA. The company is focused on marketing and building its network of key opinion leaders across the U.S. This will help company to promote and position its product in the U.S market.
Similarly, in 2019, Biogennix LLC, an osteobiologics company that manufactures bone graft products used for bone fusion procedures, received the U.S FDA 510(k) clearance for Agilon, a new collagen-enhanced bone graft material. The company has made this product commercially available in the U.S market. With the launch, the company is expanding its product portfolio and address the increasing demand from the U.S market.
Key features of the study:
- This report provides in-depth analysis of the global bone regeneration materials market, market size (US$ mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players.
- It profiles key players in the global bone regeneration materials market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study are Sigma Graft, NovaBone, B&B Dental, Stryker Corporation, J Morita USA, Kerr Restoratives, Septodont, Citagenix and Ethoss Regeneration Ltd.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global bone regeneration materials market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for Infertility drugs and devices market, research and consulting firms, new entrants, and financial analysts.
Detailed Segmentation:
Global bone regeneration materials market, By Product Type:
- Xenogene Bone Materials
- Partially Synthetic Materials
- Synthetic Materials
- Others
Global bone regeneration materials market, By Application:
- Orthopaedic Surgery
- Bone Trauma
- Dental Surgery
- Others
Global bone regeneration materials market, By Region:
- North America
By Country:
- U.S.
- Canada
- Europe
By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Latin America
By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Zimmer Biomet*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Sigma Graft
- NovaBone
- B&B Dental
- Stryker Corporation
- J Morita USA
- Kerr Restoratives
- Septodont
- Citagenix
- Ethoss Regeneration Ltd.
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
2. Market Overview
3. Market Dynamics, Regulations, and Trends Analysis
4. Global Bone Regeneration Material Market, by COVID-19 Impact Analysis
5. Global Bone Regeneration Material Market, By Product Type, 2016 - 2027, (US$ Million)
6. Global Bone Regeneration Material Market, By Application, 2016 - 2027, (US$ million)
7. Global Bone Regeneration Material Market, By Region, 2016- 2027, (US$ Million)
8. Competitive Landscape
9. Section
Companies Mentioned
A selection of companies mentioned in this report includes:
- Zimmer Biomet
- Sigma Graft
- NovaBone
- B&B Dental
- Stryker Corporation
- J Morita USA
- Kerr Restoratives
- Septodont
- Citagenix
- Ethoss Regeneration Ltd.